RA
GMAB icon

RFG Advisory’s Genmab GMAB Stock Holding History

RFG Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,318
Closed -$1.3M – 1008
2025
Q3 		$1.3M Buy
+42,318
New +$1.03M 0.03% 427

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RFG Advisory's GMAB Position: Q4 2025 in Review

RFG Advisory sold out of Genmab (GMAB) in Q4 2025, closing a stake of 42,318 shares — an estimated $1.3M sold.

RFG Advisory first reported a position in GMAB in Q3 2025 and held it in 1 quarter. The position peaked at $1.3M in Q3 2025. 293 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

  • RFG Advisory reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
  • RFG Advisory sold 42,318 Genmab shares in Q4 2025, an estimated $1.3M.
  • RFG Advisory first reported a position in Genmab in Q3 2025 and held it in 1 quarter.
  • RFG Advisory's Genmab position peaked at $1.3M in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on RFG Advisory's 13F filing for Q4 2025, filed 3 Feb 2026.